Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Bristol Myers Squibb's Opdivo (nivolumab) wins FDA approval for treatment-naïve classical Hodgkin lymphoma
Antibody, cancer, monoclonal antibody, Hodgkin lymphoma, PD-1 inhibitor, combination therapy - Read more

Globant, PharmaMar collaborate on AI-powered oncology drug discovery platform with 90% accuracy
Research collaboration, oncology, AI/ML, drug discovery - Read more

Novartis acquires Synnovation Therapeutics' Pikavation for $2B upfront to expand PI3Kα breast cancer portfolio
Small molecule, oncology, strategic, major transaction - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Dizal's ZEGFROVY (sunvozertinib) meets Ph3 primary endpoint for first-line non-small cell lung cancer treatment
Small molecule, cancer, EGFR inhibitor, non-small cell lung cancer, EGFR exon 20 insertion mutation - Read more

Earendil Labs raises $787M funding, AI-powered drugmaker developing biologics for autoimmune conditions and cancer
AI/ML platform, autoimmune, oncology, bispecific antibodies, clinical-stage, biologics - Read more

Verily Health raises $300M investment round, accelerating AI precision health platform
AI/ML platform, precision health, data analytics, clinical research platform - Read more

Azitra raises $31.4M private placement, precision dermatology therapies and cosmetic ingredients
Dermatology, microbial genetic engineering, protein design, clinical-stage - Read more

Sanofi launches first China Innovation and Operation Center in Chengdu, targeting 600 professional posts by 2026
Insulin, diabetes, strategic, operational, major investment - Read more

Truist Securities says biopharma could outperform broader markets amid Middle East geopolitical conflict volatility
Investment, strategic, financial, geopolitical risk - Read more

Indian generics including Sun Pharma, Dr. Reddy's launch cheaper semaglutide versions as Novo Nordisk patents expire
GLP-1 receptor agonist, diabetes, competitive, patent expiry, market access, cost reduction - Read more

NICE to revisit Eli Lilly's Kisunla and Eisai's Leqembi after successful cost-effectiveness appeal
Monoclonal antibody, neurological, regulatory, cost reduction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Gilead Sciences, Assembly Biosciences end HBV antiviral ABI-4334 partnership, Assembly seeks new partner
Licensing deal, infectious disease, small molecule, milestone payments - Read more

Roche discontinues emugrobart (myostatin inhibitor) development for spinal muscular atrophy after disappointing Ph2 trial results
Antibody, neurological, monoclonal antibody, spinal muscular atrophy, myostatin inhibitor - Read more

HHS denies CDC vaccine advisory committee disbandment claims following court ruling on reconstitution procedures
Vaccine, infectious disease, regulatory, operational - Read more

FDA adds seizure warning to carbidopa/levodopa Parkinson's drugs after identifying 14 vitamin B6 deficiency cases
Small molecule, neurological, regulatory, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here